DOI: 10.4244/EIJV15I14A219

Going ultra!

Thierry Lefèvre1, MD

Since Alain Cribier performed the first compassionate intervention in April 2002, the SAPIEN valve has undergone continuous improvements which were incorporated into the design of the SAPIEN XT, SAPIEN 3 (S3) and more recently the SAPIEN 3 Ultra (all Edwards Lifesciences, Irvine, CA, USA).

The development of the SAPIEN 3 Ultra (fifth-generation balloon-expandable valve) was initiated several years ago. The objective was to simplify the procedure by using a new version of the eSheath™ (Axela; Edwards Lifesciences), a delivery system with an enhanced profile, and an on-balloon valve crimping system in order to obviate the need for positioning the valve on the balloon in the descending aorta. The design of the valve’s metallic structure has been slightly modified, but the height of the deployed valve is the same as that of the S3; the outer skirt is 40% higher compared to the S3 and has greater absorption properties in order to reduce the risk of paravalvular leak (PVL) further (Figure 1).

Figure 1. Comparison between the SAPIEN 3 and the SAPIEN 3 Ultra transcatheter heart valves.

During the recently held PCR London Valves meeting, John Webb presented the first results achieved with the SAPIEN 3 Ultra in a prospective, multicentre study conducted in Canada and the UK which included 83 relatively selected intermediate-risk patients with calcific aortic stenosis in a tricuspid valve, a mean age of 83 and an STS score of 3.6 (Webb J. A prospective multicentre study of the SAPIEN 3 Ultra system in intermediate-risk patients with severe aortic stenosis. Presented at PCR London Valves, London, 18 November 2019). Procedural success (freedom from mortality, conversion to surgery and moderate to severe PVL) was achieved in 100% of cases with 0% moderate to severe PVL and single-digit new pacemaker implantation at 30 days.

In this issue of EuroIntervention, Saia et al1 present in turn the results of a European, multicentre, prospective medium-sized study conducted in 130 all-comers (mean age of 81, logistic EuroSCORE of 14% and an STS score of 3.8) who were treated with the SAPIEN 3 Ultra valve (20, 23, 26 mm) and the SAPIEN 3 (29 mm), the Axela eSheath and the Ultra delivery system. The SAPIEN 3 Ultra obtained CE marking in November 2018; patients were included consecutively in selected centres from November 2018 to February 2019.

Notwithstanding the intrinsic limitations of an observational study with unavoidable inclusion and operator bias on account of previous experience, the 30-day results are as encouraging as those presented by John Webb, namely, 100% implantation success, no stroke, no myocardial infarction, 2.2% rate of major vascular complications, 1.4% >grade I PVL and, above all, an exceptionally low rate of pacemaker implantation which was required in only 4.4% of patients at 30 days.

The SAPIEN 3 Ultra was launched on 3 January 2019 in the USA. In July 2019, Edwards Lifesciences sent an urgent field safety notice to customers, warning them that they had received reports of burst balloons during implantation procedures and insisting on the usual recommendations for safe valve deployment. In August 2019, the FDA recalled the SAPIEN 3 Ultra delivery system and issued similar recommendations for optimal use of the Ultra valve.

Since the FDA recall and based on feedback from the valve’s users, the SAPIEN 3 Ultra is now distributed with the valve pre-mounted on the classic Commander delivery system (Edwards Lifesciences) and the eSheath previously designed for the SAPIEN 3.

There is very little doubt that in the near future the SAPIEN 3 Ultra will be worthy of its name with a valve crimped on the balloon using a dedicated delivery system and an eSheath living up to our expectations.

Conflict of interest statement

T. Lefèvre reports being a proctor for Edwards Lifesciences, Boston Scientific and Abbott.

Supplementary data

To read the full content of this article, please download the PDF.

Volume 15 Number 14
Feb 20, 2020
Volume 15 Number 14
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV8SQA15 Sep 30, 2012
Edwards SAPIEN 3 valve
Binder R et al
free

Editorial

10.4244/EIJ-E-23-00009 Apr 24, 2023
SAPIEN 3 Ultra: better sealing, reduced paravalvular leak and a move in the right direction?
Reardon MJ and Goel SS
free

Original Research

10.4244/EIJ-D-23-00996 May 10, 2024
Performance and outcomes of the SAPIEN 3 Ultra RESILIA transcatheter heart valve in the OCEAN-TAVI registry
Yamamoto M et al

CLINICAL RESEARCH

10.4244/EIJV12I2A37 Jun 10, 2016
Thirty-day outcomes in patients at intermediate risk for surgery from the SAPIEN 3 European approval trial
Vahanian A et al
free
Trending articles
151.43

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
55.9

Clinical research

10.4244/EIJ-D-22-00621 Feb 20, 2023
Long-term changes in coronary physiology after aortic valve replacement
Sabbah M et al
free
54.9

Expert review

10.4244/EIJ-D-21-01010 Jun 24, 2022
Device-related thrombus following left atrial appendage occlusion
Simard T et al
free
43.75

Clinical Research

10.4244/EIJ-D-21-01091 Aug 5, 2022
Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study
Medranda G et al
free
39.95

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved